CN1454257B - 重组凝血因子在人类细胞系中的生产 - Google Patents

重组凝血因子在人类细胞系中的生产 Download PDF

Info

Publication number
CN1454257B
CN1454257B CN018097456A CN01809745A CN1454257B CN 1454257 B CN1454257 B CN 1454257B CN 018097456 A CN018097456 A CN 018097456A CN 01809745 A CN01809745 A CN 01809745A CN 1454257 B CN1454257 B CN 1454257B
Authority
CN
China
Prior art keywords
leu
ser
glu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN018097456A
Other languages
English (en)
Chinese (zh)
Other versions
CN1454257A (zh
Inventor
C·豪泽尔
A·赫尔斯特
C·施雷德尔
M·勒内雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octagene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Octagene GmbH filed Critical Octagene GmbH
Publication of CN1454257A publication Critical patent/CN1454257A/zh
Application granted granted Critical
Publication of CN1454257B publication Critical patent/CN1454257B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN018097456A 2000-03-22 2001-03-21 重组凝血因子在人类细胞系中的生产 Expired - Lifetime CN1454257B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00106225.6 2000-03-22
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08
US60/203,249 2000-05-08

Publications (2)

Publication Number Publication Date
CN1454257A CN1454257A (zh) 2003-11-05
CN1454257B true CN1454257B (zh) 2013-01-16

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018097456A Expired - Lifetime CN1454257B (zh) 2000-03-22 2001-03-21 重组凝血因子在人类细胞系中的生产

Country Status (28)

Country Link
US (1) US7572619B2 (enExample)
EP (2) EP1266006B1 (enExample)
JP (1) JP3894795B2 (enExample)
KR (1) KR100581574B1 (enExample)
CN (1) CN1454257B (enExample)
AT (1) ATE312176T1 (enExample)
AU (3) AU2001254715B2 (enExample)
BE (1) BE2014C077I2 (enExample)
BG (1) BG65930B1 (enExample)
BR (1) BRPI0109494B8 (enExample)
CA (1) CA2404163C (enExample)
CZ (1) CZ303929B6 (enExample)
DE (1) DE60115613T2 (enExample)
DK (1) DK1266006T3 (enExample)
EA (1) EA004317B1 (enExample)
EE (1) EE200200538A (enExample)
ES (1) ES2254403T3 (enExample)
FR (1) FR15C0003I2 (enExample)
HR (1) HRP20020767B1 (enExample)
HU (1) HU228091B1 (enExample)
IL (2) IL151857A0 (enExample)
MX (1) MXPA02009221A (enExample)
NO (1) NO330910B1 (enExample)
NZ (1) NZ521732A (enExample)
RS (1) RS50743B (enExample)
SI (1) SI1266006T1 (enExample)
SK (1) SK287706B6 (enExample)
WO (1) WO2001070968A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
WO2002024723A1 (en) * 2000-09-19 2002-03-28 Emory University Modified factor viii
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101120085B (zh) * 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
ES2440487T3 (es) 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
CA3090908A1 (en) * 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2198870A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
CA2776503C (en) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
EP3626737B1 (en) 2011-05-13 2023-11-29 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP2787081A4 (en) 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
SG11201808422QA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Gene therapy for treating hemophilia a
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
WO2020086686A2 (en) 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
EP0218713B1 (en) 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
JP2865861B2 (ja) * 1989-11-17 1999-03-08 ノボ ノルディスク アクティーゼルスカブ 第▲ｖｉｉｉ▼：ｃ因子活性を有するタンパク質複合体およびその製法
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ES2052368T3 (es) 1990-01-26 1994-07-01 Immuno Ag Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
JPH08511423A (ja) * 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
EP0915975A2 (en) * 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2362970A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
DE60115613D1 (de) 2006-01-12
US20040023333A1 (en) 2004-02-05
RS50743B (sr) 2010-08-31
AU2006201848A1 (en) 2006-05-25
MXPA02009221A (es) 2005-07-25
KR100581574B1 (ko) 2006-05-22
SK287706B6 (en) 2011-07-06
BG65930B1 (bg) 2010-05-31
SI1266006T1 (sl) 2006-06-30
YU71002A (sh) 2005-11-28
NZ521732A (en) 2004-05-28
NO330910B1 (no) 2011-08-15
BE2014C077I2 (enExample) 2020-01-30
KR20030011079A (ko) 2003-02-06
ES2254403T3 (es) 2006-06-16
NO20024475L (no) 2002-11-20
NO20024475D0 (no) 2002-09-19
JP2003530093A (ja) 2003-10-14
EP1460131A2 (en) 2004-09-22
WO2001070968A2 (en) 2001-09-27
EE200200538A (et) 2004-04-15
HU228091B1 (en) 2012-10-29
JP3894795B2 (ja) 2007-03-22
EA200201008A1 (ru) 2003-02-27
IL151857A0 (en) 2003-04-10
IL151857A (en) 2010-05-31
CA2404163A1 (en) 2001-09-27
CZ20023166A3 (cs) 2003-02-12
ATE312176T1 (de) 2005-12-15
EP1266006B1 (en) 2005-12-07
SK15042002A3 (sk) 2003-09-11
BRPI0109494B8 (pt) 2021-05-25
AU5471501A (en) 2001-10-03
HUP0300588A3 (en) 2005-09-28
EP1266006A2 (en) 2002-12-18
US7572619B2 (en) 2009-08-11
CZ303929B6 (cs) 2013-07-03
DK1266006T3 (da) 2006-01-16
FR15C0003I1 (fr) 2015-02-27
BR0109494A (pt) 2002-12-10
CN1454257A (zh) 2003-11-05
DE60115613T2 (de) 2006-08-24
EA004317B1 (ru) 2004-02-26
HRP20020767A2 (en) 2005-02-28
HUP0300588A2 (hu) 2003-06-28
BRPI0109494B1 (pt) 2021-05-11
HRP20020767B1 (hr) 2011-09-30
FR15C0003I2 (fr) 2015-11-20
WO2001070968A3 (en) 2001-12-13
BG107152A (bg) 2003-06-30
CA2404163C (en) 2009-09-29
AU2001254715B2 (en) 2006-02-02
EP1460131A3 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
CN1454257B (zh) 重组凝血因子在人类细胞系中的生产
JP2888518B2 (ja) 改良型の組換え発現
AU2016337408B2 (en) Inducible modification of a cell genome
JP6909203B2 (ja) 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP2749083B2 (ja) 活性化されたヒトプロテインｃの直接発現のためのベクターおよび化合物
US7125841B2 (en) Mutant human factor IX with an increased resistance to inhibition by heparin
JP2561677B2 (ja) プロテインｃの発現
CN112912112B (zh) 肝特异性核酸调节元件以及其方法及用途
AU2001254715A1 (en) Production of recombinant blood clotting factors in human cell lines
PT1863920E (pt) Método para isolamento melhorado de proteínas recombinantemente produzidas
JPH0640942A (ja) 機能的な第ｖｉｉｉ因子の製造方法
KR20080022086A (ko) 변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
KR20080107385A (ko) 변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
KR101921698B1 (ko) 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
CN111733174B (zh) 一种分离的核酸分子及其用途
CN113260704B (zh) CYP4V2和RdCVF在制备药物中的用途
PL207713B1 (pl) Muteina czynnika VIII, kodująca ją sekwencja DNA, wektor obejmujący sekwencję DNA, komórka gospodarza stransformowana tym wektorem, sposób wytwarzania muteiny czynnika VIII, kompozycja farmaceutyczna, zastosowanie muteiny czynnika VIII lub wektora i linia unieśmiertelnionych komórek ludzkich
JPS61263926A (ja) 第ｉｘ因子タンパク質の製造方法
JP3422963B2 (ja) ペプチドおよびその用途
AU2019273200B2 (en) Novel vector and use thereof
TW201307382A (zh) 因子ｖｉｉ／ｖｉｉａ之量產方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: OCTAPHARMA AG

Free format text: FORMER OWNER: OCTAGENE GMBH

Effective date: 20140905

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140905

Address after: Swiss Lan Qin

Patentee after: Octapharma AG

Address before: German Martin Slade

Patentee before: Octagene GmbH

CX01 Expiry of patent term

Granted publication date: 20130116

CX01 Expiry of patent term